2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 77. PMID: 28923102, PMCID: PMC5604351, DOI: 10.1186/s40425-017-0278-6.Peer-Reviewed Original ResearchConceptsImmunotherapy of cancerCancer immunologyHumanized modelImmunotherapy researchImmune-targeted therapiesAntitumor immune responseCancer immunotherapy researchCancer immunotherapyImmune responseMurine modelMouse modelImmunotherapyPredictive valueSubsequent panel discussionNational HarborAnnual MeetingImmunologyDrug developmentCancerMiceFuture directionsImmunocompetentTherapyCancer modeling
2011
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. The Yale Journal Of Biology And Medicine 2011, 84: 409-21. PMID: 22180678, PMCID: PMC3238327.Peer-Reviewed Original ResearchConceptsB7-H1/PDTumor-associated antigensImmune responseCancer immunotherapyMolecular pathwaysCancer-specific immune responsesImmune-mediated destructionSpecific immune responseCancer immunotherapy researchAnti-cancer effectsCoinhibitory functionImmunotherapeutic modalitiesCoinhibitory moleculesClinical evidenceImmunotherapy researchMalignant diseaseNew immunotherapeuticsImmune cellsImmune functionStromal cellsCancerMonoclonal antibodiesCancer cellsImmunotherapyCurrent knowledgeIntegrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings Of The National Academy Of Sciences Of The United States Of America 2011, 108: 16723-16728. PMID: 21933959, PMCID: PMC3189057, DOI: 10.1073/pnas.1110814108.Peer-Reviewed Original ResearchConceptsNY-ESO-1-seropositive patientsNY-ESO-1 antibodyT cell responsesClinical benefitImmune responseIpilimumab treatmentNY-ESO-1 immune responsesNY-ESO-1 serum antibodyTumor antigen-specific immune responsesCytotoxic T-lymphocyte antigen-4NY-ESO-1 immunityT-lymphocyte antigen-4Antigen-specific immune responsesIpilimumab-treated patientsAdvanced melanoma patientsAdvanced metastatic melanomaCancer/testis antigensSubset of patientsNY-ESO-1Significant survival advantageCD8 responsesAdoptive transferClinical outcomesMelanoma patientsProspective studyMolecular Markers of Response to Treatment for Melanoma
Sznol M. Molecular Markers of Response to Treatment for Melanoma. The Cancer Journal 2011, 17: 127-133. PMID: 21427556, DOI: 10.1097/ppo.0b013e318212dd5a.Peer-Reviewed Original ResearchConceptsImmune therapyAnti-tumor immune responseInitial high response rateStandard of careFraction of patientsUseful predictive biomarkerHigh response rateMost patientsMetastatic melanomaPredictive biomarkersClinical activityImmune responseIndividual patientsPotent small molecule inhibitorsDurable benefitMultiple active agentsSmall molecule inhibitorsResponse ratePatientsMutant BRAFOverall populationTherapyMolecule inhibitorsMelanomaTumors
2010
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies. Seminars In Oncology 2010, 37: 508-516. PMID: 21074066, DOI: 10.1053/j.seminoncol.2010.09.008.Peer-Reviewed Original ResearchConceptsDurable objective responsesPotent cellular immunityAnti-CD137 antibodyCellular immune responsesLigand PD-L1Reasonable safety profileSevere liver toxicityTumor response criteriaTransplantable murine tumorsDose-dependent effectSurface of antigenImmunostimulatory mAbsAntitumor immunityObjective responseDeath-1PD-L1Tumor immunityCellular immunitySafety profileLiver toxicityClinical activityT lymphocytesImmune responseTumor antigensAgonist antibody
2009
Betting on immunotherapy for melanoma
Sznol M. Betting on immunotherapy for melanoma. Current Oncology Reports 2009, 11: 397-404. PMID: 19679015, DOI: 10.1007/s11912-009-0053-z.Peer-Reviewed Original ResearchConceptsAdvanced melanomaAntigen-specific T cell expansionEffective antitumor immune responseAntitumor immune responseEffective treatment optionT cell expansionAntigen-specific lymphocytesTumor defense mechanismsDurable remissionsPreparative regimensConditioning regimensAdoptive immunotherapyImmune therapyCancer vaccinesImmune activationTreatment optionsPredictive biomarkersPrimary tumorTumor immunobiologyClinical trialsAntigen presentationImmune responseHigh riskNew cytokinePatients
2007
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. A Clinical Development Paradigm for Cancer Vaccines and Related Biologics. Journal Of Immunotherapy 2007, 30: 1-15. PMID: 17198079, DOI: 10.1097/01.cji.0000211341.88835.ae.Peer-Reviewed Original ResearchConceptsTherapeutic cancer vaccinesPhase 2 trialCancer vaccinesEfficacy trialsPrinciple trialImmune responseEnd pointCytotoxic agentsCombination therapyRelated biologicsBiologic activitySingle-arm phase 2 trialRandomized phase 2 trialClinical development challengesRandomized phase 2Primary end pointStudy end pointTumor response ratePhase 3 studyPhase 3 trialClinical end pointsNovel cancer vaccinesDifferent clinical characteristicsSuch immune responsesClinical development plan